Nature Medicine is a well-respected journal and generally decently trusted (though naturally some papers can get through the cracks). Perhaps that occurred, but I cannot say. I skimmed the paper and the results are significant/impactful, which would make it an attractive paper to publish even if there could be potential controversy. There was no evident disclosure of the authors on the pdf, which is troubling. I personally would want to see the trial reproduced by another group before I believed much. I did not have a chance to also take a look at the dosing they used for it, such as if it was a very low dose yet still providing potential clinical benefit. FDA review of the indication would help address any issues. Public perception of the care the FDA takes does not quite match reality. I can see why it is significant considering the societal impact of PTSD with need for improved management of the condition. We will see in the future if the results hold up as FDA approval also typically requires a phase 4 clinical trial (continuing to keep an eye on the therapy even after it is approved).